Manufacturing projects at TBD’s sites commonly originate from completed in-house API development or through customer-led tech transfer. TBD can manufacture market-approved generics, cGMP innovative molecules required for early phase clinical trials, or any other custom small-molecules such as excipients, intermediates or impurities. Product specs are tailored to meet industry needs such as GMP compliance, and other client requirements.
Currently, a new production facility is in construction in Tartu, Estonia. The new facility will significantly increase the range of capacity on offer.